Whale Large Capital
  • Politics
  • World News
  • Business
  • Investing
  • Politics
  • World News
  • Business
  • Investing

Whale Large Capital

Politics

Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

by November 26, 2024
November 26, 2024
Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

The Biden administration is expanding coverage of anti-obesity drugs such as Ozempic and Wegovy for people with Medicare and Medicaid through a new proposal from the Department of Health and Human Services, a White House official says. 

Medicare currently only covers these drugs for people who are diagnosed with diabetes or cardiovascular disease with obesity, or for people who are overweight, according to the official, who added that while some state Medicaid programs cover the GLP-1 medications for obesity, many do not. 

The new HHS proposal, they said, would require both Medicare and Medicaid to cover the drugs for people with obesity as a treatment for the condition.

‘Today’s new proposal would expand access to these innovative medications for obesity, which is widely recognized as a disease and help an estimated 3.4 million Americans with Medicare. Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95 percent for some enrollees,’ the White House said in a statement Tuesday. 

‘Approximately 4 million adult Medicaid enrollees would also gain new access to these medications. This proposal would allow Americans and their doctors to determine the best path forward so they can lead healthier lives, without worrying about their ability to cover these drugs out-of-pocket, and ultimately reduce health care costs to our nation,’ the statement added. 

The White House says that ‘for too many Americans, these critical treatments are too expensive and therefore out of reach,’ and, ‘without insurance coverage, these drugs can cost someone as much as $1,000 a month.’

GLP-1 (glucagon-like peptide) receptor agonists are commonly prescribed to patients with type 2 diabetes (to stabilize blood glucose levels) or obesity (to assist with weight loss). 

‘These medications slow down digestion, which means food stays in the stomach longer,’ said Dr. Alfred Bonati, the founder of the Bonati Spine Institute in Florida, previously told Fox News Digital. 

The White House says an estimated 42 million Americans today have obesity, ‘with increased risk of all-cause mortality and multiple related comorbidities such as diabetes, cardiovascular disease, stroke, some cancers, and more.’ 

‘Over the past few years, there have been major scientific advancements in the treatment of obesity, with the introduction of new life-saving drugs. These anti-obesity medications can help prevent the development of Type 2 diabetes. Furthermore, these drugs reduce deaths and sickness from heart attack and other cardiovascular outcomes by up to 20%,’ the White House added. 

Fox News’ Melissa Rudy contributed to this report. 

This post appeared first on FOX NEWS
0
FacebookTwitterGoogle +Pinterest
previous post
World’s oldest man, John Tinniswood, dies aged 112
next post
Spanish retailer Mango to open 60 new U.S. stores as it looks to elevate the brand

You may also like

State Department issues worldwide caution for US travelers...

June 23, 2025

Misdirection and ‘deception’ likely key in Trump admin’s...

June 22, 2025

Epstein client list release could be imminent after...

February 27, 2025

New House GOP resolution eviscerates Comey over ’86...

May 16, 2025

On Reagan’s birthday, how he and Trump helped...

February 6, 2025

‘Not a conspiracy theorist’: Harris fundraiser floats idea...

September 5, 2024

Byron Donalds unleashes on Dem Trump ‘lies,’ says...

November 10, 2024

Trump pushes tax hikes for wealthy as ‘big,...

May 9, 2025

BRENT BOZELL: The surprising way Donald Trump can...

October 31, 2024

11 Dems join GOP lawmakers to threaten UN...

October 25, 2024

    Subscribe today to receive exclusive access to all our retirement secrets and income strategies, including special financial news and updates from our experts. From time to time, our newsletters feature valuable insights and analysis on the latest financial trends. Don't miss out on these exclusive updates – join our subscription to stay informed!


    By opting in you agree to receive emails from us. Your information is secure and your privacy is protected.



    Latest

    • White House pushes back forcefully on Epstein file criticism: ‘Asinine suggestion’

      July 17, 2025
    • ‘Irrelevant’: Senators push back against Vought’s call for more partisan spending process

      July 17, 2025
    • Biden-era policy indirectly paying for unaccompanied minors’ abortions rescinded by Trump DOJ

      July 17, 2025
    • Unearthed chat sheds light on cozy ties between judges, climate activists, raising ethical concerns

      July 17, 2025
    • Not ‘honest’ news organizations: White House defends yanking $9B ‘worth of crap’ in rescissions package

      July 17, 2025
    • Rubio bans overseas outposts commenting on foreign elections unless there’s ‘clear and compelling’ US interest

      July 17, 2025

    Categories

    • Business (719)
    • Investing (661)
    • Politics (4,961)
    • World News (3,213)
    • Terms & Conditions
    • Privacy Policy
    • Contact us
    • About us

    Disclaimer: WhaleLargeCapital.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 WhaleLargeCapital.com | All Rights Reserved